Get the Stockscreener App
13.16
3.59%
-0.49
PepGen Inc stock is currently priced at $13.16, with a 24-hour trading volume of 40,941.
It has seen a -3.59% decreased in the last 24 hours and a +14.43% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $13.53 pivot point. If it approaches the $12.80 support level, significant changes may occur.
Previous Close:
$13.65
Open:
$13.82
24h Volume:
40,941
Market Cap:
$426.61M
Revenue:
-
Net Income/Loss:
$-78.63M
P/E Ratio:
-4.4916
EPS:
-2.9299
Net Cash Flow:
$-71.60M
1W Performance:
-6.07%
1M Performance:
+14.43%
6M Performance:
+229.00%
1Y Performance:
-9.37%
1D Range:
$13.16
$13.90
52W Range:
$3.72
$17.51
PepGen Inc Stock (PEPG) Company Profile
Name
PepGen Inc
Sector
Industry
Phone
781-797-0979
Address
245 Main Street, 2nd Floor, Cambridge
PepGen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
PepGen Inc Stock (PEPG) Latest News
PepGen executive sells shares worth over $134,000 - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
HC Wainwright Analysts Reduce Earnings Estimates for PepGen Inc. (NASDAQ:PEPG) - Defense World
Defense World
Q2 2024 Earnings Estimate for PepGen Inc. (NASDAQ:PEPG) Issued By Wedbush - Defense World
Defense World
Brokers Offer Predictions for PepGen Inc.'s Q2 2024 Earnings (NASDAQ:PEPG) - Defense World
Defense World
PepGen executive sells shares worth over $134,000 By Investing.com - Investing.com
Investing.com
Brokers Issue Forecasts for PepGen Inc.'s Q2 2024 Earnings (NASDAQ:PEPG) - MarketBeat
MarketBeat
PepGen Inc Stock (PEPG) Financials Data
PepGen Inc (PEPG) Net Income 2024
PEPG net income (TTM) was -$78.63 million for the quarter ending December 31, 2023, a -13.78% decrease year-over-year.
PepGen Inc (PEPG) Cash Flow 2024
PEPG recorded a free cash flow (TTM) of -$71.60 million for the quarter ending December 31, 2023, a -13.61% decrease year-over-year.
PepGen Inc (PEPG) Earnings per Share 2024
PEPG earnings per share (TTM) was -$3.30 for the quarter ending December 31, 2023, a +6.70% growth year-over-year.
PepGen Inc Stock (PEPG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 09 '24 |
Buy |
10.64 |
2,557,593 |
27,212,790 |
9,179,273 |
| McArthur James G | President and CEO |
Nov 30 '23 |
Buy |
4.17 |
1,694 |
7,056 |
1,694 |
| McArthur James G | President and CEO |
Jun 08 '23 |
Option Exercise |
2.71 |
2,381 |
6,453 |
2,381 |
| McArthur James G | President and CEO |
Jun 08 '23 |
Sale |
16.04 |
2,381 |
38,188 |
0 |
| McArthur James G | President and CEO |
Jun 07 '23 |
Option Exercise |
2.71 |
8,419 |
22,815 |
8,419 |
| McArthur James G | President and CEO |
Jun 07 '23 |
Sale |
16.23 |
8,419 |
136,618 |
0 |
| McArthur James G | President and CEO |
Jun 06 '23 |
Option Exercise |
2.71 |
18,150 |
49,186 |
18,150 |
| McArthur James G | President and CEO |
Jun 06 '23 |
Sale |
16.18 |
18,150 |
293,660 |
0 |
| McArthur James G | President and CEO |
Jun 05 '23 |
Option Exercise |
2.71 |
500 |
1,355 |
500 |
| McArthur James G | President and CEO |
Jun 05 '23 |
Sale |
16.06 |
500 |
8,028 |
0 |
About PepGen Inc
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
0.77%
1.20%
Cap:
|
Volume (24h):